Scientists Built a Better CBD for Epilepsy—From Spearmint, Not Cannabis

Structure-activity relationship study using EEG-based assessment in mice. Tested a library of carvone-derived CBD (+) enantiomers with varying alkyl chain lengths. Seizure resilience tested in both wildtype mice and the Gabra2-1 developmental epilepsy model. Administration routes included pre-treatment and 5-day oral gavage during postnatal development.

Current anti-seizure medications for developmental epilepsy have significant limitations: many patients are treatment-resistant, and standard drugs that target GABA signaling can harm the developing brain. Natural CBD helps some patients but not all. These synthetic CBD analogues could expand the toolkit—and because they're derived from spearmint rather than cannabis, they sidestep some of the regulatory and supply chain issues that complicate cannabis-derived medicines.

This represents a broader trend in cannabinoid pharmacology: moving from crude plant extracts to precision-designed molecules that target specific mechanisms. While Epidiolex (pharmaceutical CBD) was a landmark approval for Dravet and Lennox-Gastaut syndromes, these carvone-derived variants could address the many epilepsy patients for whom CBD alone isn't enough. The non-cannabis source also matters for global access, since many countries restrict cannabis-derived products regardless of their psychoactive properties.

All data from mouse models—no human testing yet. The Gabra2-1 model represents one specific type of developmental epilepsy; results may not generalize to other epilepsy syndromes. Long-term safety of these novel compounds is unknown. The gap between promising preclinical results and clinical efficacy is notoriously large in epilepsy drug development.